QP-Prostate® CAD vs TumorSight Viz

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

QP-Prostate® CAD

by Quibim S.L.

TumorSight Viz

by SimBioSys

AI Verdict

Tool A, QP-Prostate® CAD, is designed to assist radiologists in the detection and diagnosis of clinically significant prostate cancer using MRI, offering features like lesion detection, risk scoring, and structured reporting. In contrast, Tool B, TumorSight Viz, focuses on breast cancer, converting standard breast MRI into 3D models to facilitate precision surgical planning and enhance patient understanding. While both are FDA-cleared, AI-powered oncology solutions that utilize MRI for tumor analysis and 3D visualization, their distinct target organs and primary clinical applications (diagnosis vs. surgical planning) make them suitable for different stages of cancer care.

Choose QP-Prostate® CAD if…

Choose QP-Prostate® CAD if your primary need is to enhance the diagnostic accuracy and streamline the workflow for detecting and characterizing clinically significant prostate cancer. This tool is ideal for radiologists seeking AI-powered automatic lesion detection, quantitative metrics, and structured PI-RADS reporting to improve prostate MRI interpretation and diagnosis.

View QP-Prostate® CAD →

Choose TumorSight Viz if…

Choose TumorSight Viz if your focus is on precision surgical planning and improving patient understanding for breast cancer. This platform is best suited for surgeons and care teams who need to transform standard breast MRIs into intuitive 3D models, visualize tumor spatial relationships, and facilitate shared decision-making with patients regarding breast conservation surgery.

View TumorSight Viz →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	QP-Prostate® CAD	TumorSight Viz
Pricing	Contact for pricing	Subscription-based
Deployment	Cloud-based, with integration into standard reading environments (PACS) and AI marketplaces.	Cloud-based platform
FDA Status	1 AI-estimated	1 AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

QP-Prostate® CAD

Tool A emphasizes seamless integration into standard reading environments like PACS and AI marketplaces, along with providing a PI-RADS 2.1 structured report template. This focus on streamlining existing clinical workflows for radiologists gives it a slight edge in practical usability within the diagnostic setting. Tool B's intuitive 3D models are valuable for broader understanding, but Tool A's features are more directly aligned with enhancing the radiologist's daily workflow.

Clinical Value

Tie

Both tools offer significant and distinct clinical value. Tool A enhances diagnostic accuracy for prostate cancer detection and diagnosis, a critical initial step, backed by training on pathology data. Tool B provides crucial 3D visualization and quantification for precision surgical planning in breast cancer, directly impacting treatment outcomes and patient understanding. Their contributions are equally vital at different stages of the cancer care pathway.

Pricing & Value

TumorSight Viz

Neither tool provides specific pricing details, making a direct comparison of value impossible. However, Tool B offers slightly more transparency by stating it is 'subscription-based' with 'different tiers,' giving potential customers a clearer idea of the pricing model compared to Tool A's generic 'Contact for pricing'.

Enterprise Readiness

QP-Prostate® CAD

Tool A explicitly states HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are fundamental requirements for healthcare enterprises. While Tool B implies these by its healthcare context and FDA clearance, Tool A's explicit declarations provide greater assurance for enterprise adoption and regulatory compliance.

Innovation

TumorSight Viz

Both tools demonstrate significant innovation in their respective fields. Tool A's AI-QUALu2122 for automated image quality assessment is a novel feature. However, Tool B's ability to transform standard 2D MRI into comprehensive 3D models for precision surgical planning and its unique research-use application to convert prone imaging to a supine operative position represent a highly transformative and innovative approach to surgical visualization and workflow.

Support & Docs

Tie

The provided structured facts do not contain any information regarding the availability or quality of support and documentation for either tool. Without this crucial information, it is not possible to distinguish between the two on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	QP-Prostate® CAD	TumorSight Viz
Name	QP-Prostateu00ae CAD	TumorSight Viz
Company	Quibim S.L.	SimBioSys
Target Cancer Type	Prostate Cancer	Breast Cancer
Primary Use Case	Detection and diagnosis of clinically significant prostate cancer using MRI, enhancing diagnostic accuracy and streamlining radiology workflows.	Transforms standard breast MRI into comprehensive 3D models for precision surgical planning and enhanced patient understanding.
Key Quantitative Outputs	Prostate volume and dimensions, Apparent Diffusion Coefficient (ADC) map, computed high b-value and perfusion metrics (K trans, K ep, V e)	Tumor volume and distances to anatomical features

Videos

Demos, reviews, and walkthroughs featuring QP-Prostate® CAD and TumorSight Viz.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What specific types of cancer do these AI tools address?

QP-Prostateu00ae CAD is an AI-powered software for the detection and diagnosis of clinically significant prostate cancer using MRI. TumorSight Viz is an AI-powered platform that transforms standard breast MRI into comprehensive 3D models for precision surgical planning in breast cancer.

What quantitative information do these tools provide to aid in diagnosis or planning?

QP-Prostateu00ae CAD provides quantitative information such as prostate volume and dimensions, Apparent Diffusion Coefficient (ADC) map, computed high b-value and perfusion metrics. TumorSight Viz offers automatic segmentation and quantification of tumor characteristics, calculating tumor volume and distances to anatomical features.

How do these tools integrate into a physician's existing workflow?

QP-Prostateu00ae CAD is cloud-based and integrates into standard reading environments (PACS) and AI marketplaces, also supporting fusion biopsy systems. TumorSight Viz is a cloud-based platform designed to convert standard breast MRI into intuitive 3D models for surgical planning.

What are the primary differences in the AI's core functionality for each tool?

QP-Prostateu00ae CAD's AI focuses on automatic lesion detection and risk scoring for clinically significant prostate cancer, prostate segmentation, and automated prostate MRI image quality assessment. TumorSight Viz's AI specializes in generating 3D spatial visualizations of breast cancer from MRI, automatic segmentation and quantification of tumor characteristics, and supporting preoperative planning.

What specific reporting or visualization features do these tools offer?

QP-Prostateu00ae CAD provides a PI-RADS 2.1 structured report template and advanced viewing with 3D visualization. TumorSight Viz converts standard breast MRI into intuitive 3D models and includes a research-use application to convert prone imaging to a supine operative position.